ATARA BIOTHERAPEUTICS, INC. Restricted Cash
ATARA BIOTHERAPEUTICS, INC. (ATRA) had Restricted Cash of $1.30 million as of 2022-09-30, per its 10-Q filed 2022-11-08.
Discontinued › Balance Sheet › Assets › Restricted Cash and Cash Equivalent
us-gaap:RestrictedCash · last filed 2022-11-08
- 2022-09-30: Restricted Cash $1.30M.
- 2022-06-30: Restricted Cash $1.30M.
- 2022-03-31: Restricted Cash $1.30M.
- 2021-12-31: Restricted Cash $1.40M.
| Period end | Restricted Cash |
|---|---|
| 2022-09-30 | $1.30M 10-Q · filed 2022-11-08 |
| 2022-06-30 | $1.30M 10-Q · filed 2022-08-08 |
| 2022-03-31 | $1.30M 10-Q · filed 2022-05-05 |
| 2021-12-31 | $1.40M 10-Q · filed 2022-11-08 |
| 2021-09-30 | $1.40M 10-Q · filed 2021-11-04 |
| 2021-06-30 | $1.40M 10-Q · filed 2021-08-09 |
| 2021-03-31 | $1.40M 10-Q · filed 2021-05-04 |
| 2020-12-31 | $1.40M 10-K · filed 2022-02-28 |
| 2020-09-30 | $1.40M 10-Q · filed 2020-11-09 |
| 2020-06-30 | $1.40M 10-Q · filed 2020-08-05 |
| 2020-03-31 | $1.40M 10-Q · filed 2020-05-06 |
| 2019-12-31 | $1.40M 10-K · filed 2021-03-01 |
| 2019-09-30 | $1.40M 10-Q · filed 2019-11-07 |
| 2019-06-30 | $1.40M 10-Q · filed 2019-08-08 |
| 2019-03-31 | $1.40M 10-Q · filed 2019-05-09 |
| 2018-12-31 | $1.40M 10-K · filed 2020-02-27 |
| 2017-12-31 | $1.40M 10-K · filed 2019-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |